Medical devices, healthcare technology and the business of care
PMA approval · P250055

AMDS Hybrid Prosthesis

Artivion, Inc · Decision date Jun 26, 2026

FDA DECISIONP250055

What did the FDA approve?

FDA records P250055 as an original PMA application. The recorded decision is approval, dated Jun 26, 2026.

FDA approval order statement

The AMDS Hybrid Prosthesis is indicated for use in patients with acute DeBakey Type I aortic dissections with malperfusion (including cerebral, visceral, renal, and peripheral malperfusion) and a primary entry tear within the ascending aorta proximal to the innominate artery, who are undergoing open surgical repair within 0-14 days of diagnosis.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Jun 26, 2026

FDA source record

Regulatory record facts

Identifier
P250055
Regulatory pathway
Premarket approval application
Applicant
Artivion, Inc
Product code
QSK
Decision code
APPR
Decision date
Jun 26, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Hybrid stent graft, thoracic aortic lesion treatment.

Applicant
Artivion, Inc
Product code
QSK
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250055 received

    Application receipt date recorded by FDA.

  2. P250055 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P250055. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code QSK

Product / regulatory recordCompanyPathwayDecision dateSource
Thoraflex HybridP210006/S018
Vascutek, Ltd.PMA supplementSep 8, 2026FDA
Thoraflex HybridP210006/S019
Vascutek, Ltd.PMA supplementJun 24, 2026FDA
Thoraflex HybridP210006/S017
Vascutek, Ltd.PMA supplementApr 20, 2026FDA
Thoraflex HybridP210006/S016
Vascutek, Ltd.PMA supplementJan 29, 2026FDA
Thoraflex HybridP210006/S015
Vascutek, Ltd.PMA supplementOct 29, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Artivion, Inc

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1655 Roberts Blvd. NW, Kennesaw, GA, 30144

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records